generally avoided Concurrent use with other potent neuroactive compounds: manage carefully Recommended precautions Always begin under physician supervision with a full medical history review Start at the lowest effective dose and titrate slowly Use cycling protocols avoid indefinite continuous use Monitor for neurological overstimulation symptoms Regular follow-up consultations during active protocols Who may be a candidate for Dihexa therapy
The preliminary therapy with decreased nerve degeneration and glial stimulation, and cytokine production, including IFN-, IL-17, IL-17A, TNF-, IL-1, and chemokines (MCP-1 and MIP-1)
By following these storage and handling guidelines, youll ensure that your DSIP is as effective as the day it was reconstituted
also showed the same trend in knee symptoms and daily activity progression using the mean KOOS score in ten participants with degenerative meniscus tears without osteoarthritis according to Stoller classification after 3 months and 6 months of follow up (i.e., KOOS: 56.6 15.7 baseline, 70.2 16.8 post- 3 months, 72.7 18.5 post- 6 months, p = 0.0007)